4-benzyl-4-[(pyridin-3-ylmethyl)-carbamoyl]-piperidine-1-carboxylic acid tert-butyl ester | 1227169-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-benzyl-4-[(pyridin-3-ylmethyl)-carbamoyl]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-benzyl-4-(pyridin-3-ylmethylcarbamoyl)piperidine-1-carboxylate
• CAS: 1227169-92-7
• 化学式: C₂₄H₃₁N₃O₃
• 分子量: 409.528
• InChiKey: XNDHTXQTIKYAIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-benzyl-4-[(pyridin-3-ylmethyl)-carbamoyl]-piperidine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 、 sodium hydroxide 、 盐酸 作用下， 以 二氯甲烷 、 乙醚 为溶剂， 以90%的产率得到4-benzyl-piperidine-4-carboxylic acid (pyridin-3-ylmethyl)-amide dihydrochloride
  参考文献：
  名称：

  QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及一种具有以下式I的化合物 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 和n如本文所定义，并且涉及其药用活性盐，外消旋混合物，对映体，光学异构体或其互变异构体形式。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

  公开号：

  US20100125078A1
• 作为产物：
  描述：

  3-氨甲基吡啶 、 N-boc-4-苄基-4-哌啶羧酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以97%的产率得到4-benzyl-4-[(pyridin-3-ylmethyl)-carbamoyl]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及一种具有以下式I的化合物 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 和n如本文所定义，并且涉及其药用活性盐，外消旋混合物，对映体，光学异构体或其互变异构体形式。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

  公开号：

  US20100125078A1

文献信息

• US8318749B2
  申请人：——

  公开号：US8318749B2

  公开（公告）日：2012-11-27
• [EN] QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE QUINAZOLINE COMME ANTAGONISTES DES RÉCEPTEURS NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010054968A1

  公开（公告）日：2010-05-20

  The present invention relates to a compounds of formula I wherein R1 is hydroxy or NR'R"; R' and R" are independently from each other hydrogen, lower alkyl, cycloalkyl, or may form together with the N-atom to which they are attached a heteroalkyl ring; R2 is hydrogen, lower alkyl, lower alkoxy, halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano or S(O)2-Iower alkyl; R3 is lower alkyl, -(CH2)m-aryl, optionally substituted by halogen, or is -(CH2)m-cycloalkyl; R4 and R5 are independently from each other hydrogen or lower alkyl substituted by halogen, or are -(CR2)m-aryl or -(CR2)m-heteroaryl, wherein the rings may be substituted by one or more substituents, selected from halogen, lower alkyl, lower alkyl substituted by halogen, cyano, hydroxy, NR'R" or by lower alkoxy substituted by halogen, or are -(CR2)m-cycloalkyl, optionally substituted by hydroxy or by aryl, or are a heteroalkyl ring, optionally substituted by =O or -(CR2)m-aryl, or R4 and R5 are together with the N-atom to which they are attached a heterocyclic ring system, optionally substituted by lower alkyl, aryl or halogen-substituted aryl, and R may be independently from each other hydrogen, lower alkyl or lower alkyl substituted by hydroxyl; n is 1 or 2; m is 0, 1 or 2; or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
• QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100125078A1

  公开（公告）日：2010-05-20

  The present invention relates to a compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein and to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下式I的化合物 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 和n如本文所定义，并且涉及其药用活性盐，外消旋混合物，对映体，光学异构体或其互变异构体形式。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。